The driver kinase
A kinase is an enzyme that flips other proteins on by attaching a phosphate group — it is one of the cell's master switches for growth and division. Normally kinases obey strict signals. But a single mutation can jam a growth kinase permanently in the on position, screaming grow, grow, grow with no off switch. When a cancer depends on that one runaway kinase to survive, biologists say the tumour is *addicted* to it — and an addiction is a beautiful thing to exploit.
The landmark case is chronic myeloid leukaemia. A genetic accident fuses two genes into a hyperactive tyrosine kinase called BCR-ABL, and that single enzyme drives the disease. Imatinib, approved in 2001, plugs into BCR-ABL and switches it off. Patients who once faced a grim prognosis now often live for decades on a daily pill. It was the proof that targeted therapy could work — that finding the one broken protein and blocking it was not a fantasy.
How the molecule does it
Almost every kinase inhibitor works by occupying the kinase's fuel slot. To do its job, a kinase must grab a molecule of ATP in a pocket and use it as the phosphate source. That ATP binding pocket is the active site, and most drugs here are simply better-shaped fakes that wedge into the same slot, blocking ATP from binding. No ATP, no phosphate transfer, no growth signal. The drug is, in effect, a molecular cork in the enzyme's most important hole.
This is where structure-based design earns its keep. With a crystal structure of the drug sitting in the pocket, chemists can see exactly which atoms touch the protein and which empty corners to reach into. They grow the molecule toward features unique to the target kinase, building in selectivity by design rather than by luck.
Resistance: the tumour fights back
Targeted therapy has a recurring tragedy. Block the addicted kinase, and the tumour shrinks — until a few cells mutate the kinase so the drug no longer fits. The classic move is a resistance mutation at the gatekeeper residue: swap a small amino acid for a bulky one, and the drug can no longer slide into the pocket, while ATP still can. The cancer comes roaring back, now deaf to that drug.
The answer is an arms race of generations. When imatinib fails in CML, second-generation drugs like dasatinib step in; when the stubborn T315I mutation defeats even those, the third-generation ponatinib was designed specifically to reach past that bulky gatekeeper. Each generation is a fresh round of chemistry aimed at a tumour that has learned the last move. Resistance is not a footnote in oncology — it is the main plot.